within Pharmacolibrary.Drugs.ATC.J;

model J05AX19
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.01,
    adminDuration  = 600,
    adminMass      = 0.125,
    adminCount     = 1,
    Vd             = 0.0075,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0003333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Tilorone is a synthetic, small-molecule antiviral agent, initially developed in the Soviet Union. It acts as an interferon inducer and is used mainly in Russia and some neighboring countries for the treatment and prophylaxis of viral infections such as influenza, hepatitis, and herpesvirus infections. Tilorone is not approved by the FDA or EMA for use in the United States or European Union.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for oral administration in adult humans, as direct published clinical PK studies are lacking in English language literature.</p><h4>References</h4><ol><li><p>Lane, TR, et al., &amp; Ekins, S (2020). Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig. <i>Antiviral research</i> 181 104863–None. DOI:<a href=&quot;https://doi.org/10.1016/j.antiviral.2020.104863&quot;>10.1016/j.antiviral.2020.104863</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32682926/&quot;>https://pubmed.ncbi.nlm.nih.gov/32682926</a></p></li><li><p>Golovenko, NY, &amp; Borisyuk, IY (2005). Pharmacokinetics of amixin after repeated peroral administration to mice. <i>Bulletin of experimental biology and medicine</i> 140(6) 708–710. DOI:<a href=&quot;https://doi.org/10.1007/s10517-006-0061-z&quot;>10.1007/s10517-006-0061-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16848231/&quot;>https://pubmed.ncbi.nlm.nih.gov/16848231</a></p></li><li><p>Vartiainen, V, et al., &amp; Myllärniemi, M (2018). Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice. <i>International journal of pharmaceutics</i> 544(1) 121–128. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2018.04.019&quot;>10.1016/j.ijpharm.2018.04.019</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29655797/&quot;>https://pubmed.ncbi.nlm.nih.gov/29655797</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AX19;
